Literature DB >> 21165628

Determination of the transient period of the EIS complex and investigation of the suppression of blood glucose levels by L-arabinose in healthy adults.

Kiyoshi Shibanuma1, Yoko Degawa, Koichi Houda.   

Abstract

PURPOSE: L-Arabinose uncompetitively inhibits intestinal sucrase by forming an enzyme-inhibitor-substrate (EIS) complex. The transient period of the EIS complex affects the time span of inhibition. We determined the apparent transient period of the EIS complex of sucrase, L-arabinose, and sucrose both in vitro and in humans.
METHODS: Intestinal acetone powder (a source of sucrase), L-arabinose, and sucrose were mixed and injected into a dialysis membrane that was placed in a sucrose solution. The production rate of D-glucose and the release rate of L-arabinose from sucrase were determined. We also investigated the suppression of blood glucose levels by L-arabinose in 21 healthy volunteers. Sucrose (40 g) was ingested with or without L-arabinose (2 g), then blood glucose values were measured, which returned to steady-state conditions within 2 h. Volunteers were then given 90 g of commercial adzuki bean jelly containing 40 g sucrose as the sucrose load, and blood glucose values were measured again.
RESULTS: Addition of L-arabinose reduced the production rate of D -glucose compared to the rates measured in the absence of L-arabinose for several hours in vitro. L-Arabinose was released at a lower rate in the presence of sucrose than in its absence. Blood glucose values measured 2 h after sucrose was given with L -arabinose were significantly lower than those measured when L-arabinose was not given (Δ change in maximum value: with L-arabinose, 53.8 ± 19.7 mg/dL; without L-arabinose, 65.0 ± 17.7 mg/dL).
CONCLUSION: The EIS complex of sucrase-L -arabinose-sucrose was maintained for several hours both in vitro and in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21165628     DOI: 10.1007/s00394-010-0154-3

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  5 in total

1.  Characterization of arabinose and ferulic acid rich pectic polysaccharides and hemicelluloses from sugar beet pulp.

Authors:  A Oosterveld; G Beldman; H A Schols; A G Voragen
Journal:  Carbohydr Res       Date:  2000-09-08       Impact factor: 2.104

2.  L-arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals.

Authors:  K Seri; K Sanai; N Matsuo; K Kawakubo; C Xue; S Inoue
Journal:  Metabolism       Date:  1996-11       Impact factor: 8.694

3.  [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].

Authors:  Noboru Kuboyama; Ichiro Hayashi; Tadashi Yamaguchi
Journal:  Nihon Yakurigaku Zasshi       Date:  2006-03

4.  L-arabinose feeding prevents increases due to dietary sucrose in lipogenic enzymes and triacylglycerol levels in rats.

Authors:  S Osaki; T Kimura; T Sugimoto; S Hizukuri; N Iritani
Journal:  J Nutr       Date:  2001-03       Impact factor: 4.798

5.  Isolation and partial characterization of feruloylated oligosaccharides from maize bran.

Authors:  L Saulnier; J Vigouroux; J F Thibault
Journal:  Carbohydr Res       Date:  1995-08-11       Impact factor: 2.104

  5 in total
  10 in total

1.  Coconut-derived D-xylose affects postprandial glucose and insulin responses in healthy individuals.

Authors:  Yun Jung Bae; Youn-Kyung Bak; Bumsik Kim; Min-Sun Kim; Jin-Hee Lee; Mi-Kyung Sung
Journal:  Nutr Res Pract       Date:  2011-12-31       Impact factor: 1.926

2.  IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety.

Authors:  Barbara Grube; Udo Bongartz; Felix Alt
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-17       Impact factor: 2.629

3.  Formulation of a Mixture of Plant Extracts for Attenuating Postprandial Glycemia and Diet-Induced Disorders in Rats.

Authors:  Adam Jurgoński; Katarzyna Billing-Marczak; Jerzy Juśkiewicz; Marcin Krotkiewski
Journal:  Molecules       Date:  2019-10-11       Impact factor: 4.411

4.  L-arabinose and D-xylose: sweet pentoses that may reduce postprandial glucose and insulin responses.

Authors:  Korrie Pol; Monica Mars
Journal:  Food Nutr Res       Date:  2021-07-23       Impact factor: 3.894

5.  L-Arabinose improves hypercholesterolemia via regulating bile acid metabolism in high-fat-high-sucrose diet-fed mice.

Authors:  Yu Wang; Jiajia Zhao; Qiang Li; Jinxin Liu; Yujie Sun; Kuiliang Zhang; Mingcong Fan; Haifeng Qian; Yan Li; Li Wang
Journal:  Nutr Metab (Lond)       Date:  2022-04-15       Impact factor: 4.654

6.  L-arabinose co-ingestion delays glucose absorption derived from sucrose in healthy men and women: a double-blind, randomised crossover trial.

Authors:  Kenneth Pasmans; Ruth C R Meex; Jorn Trommelen; Joan M G Senden; Elaine E Vaughan; Luc J C van Loon; Ellen E Blaak
Journal:  Br J Nutr       Date:  2021-10-18       Impact factor: 4.125

Review 7.  Nutritional strategies to attenuate postprandial glycemic response.

Authors:  Kenneth Pasmans; Ruth C R Meex; Luc J C van Loon; Ellen E Blaak
Journal:  Obes Rev       Date:  2022-06-10       Impact factor: 10.867

8.  Protective effects of L-arabinose in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats.

Authors:  Lei Hao; Xiaoling Lu; Min Sun; Kai Li; Lingmin Shen; Tao Wu
Journal:  Food Nutr Res       Date:  2015-12-10       Impact factor: 3.894

9.  Efficacy of L-Arabinose in Lowering Glycemic and Insulinemic Responses: The Modifying Effect of Starch and Fat.

Authors:  Korrie Pol; Marie-Luise Puhlmann; Monica Mars
Journal:  Foods       Date:  2022-01-08

10.  Rare sugars and their health effects in humans: a systematic review and narrative synthesis of the evidence from human trials.

Authors:  Amna Ahmed; Tauseef A Khan; D Dan Ramdath; Cyril W C Kendall; John L Sievenpiper
Journal:  Nutr Rev       Date:  2022-01-10       Impact factor: 7.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.